Fair and efficient use of new Alzheimer’s treatments with a risk-adjusted approach
Using the generalized risk-adjusted cost-effectiveness (GRACE) model to advance an efficient and fair use of novel treatments for Alzheimer’s Disease and Related Dementias
This project will gather input from people with Alzheimer’s, their families, and older adults to design fair ways to decide who should receive new Alzheimer’s drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11342978 on NIH RePORTER |
What this research studies
You and others affected by Alzheimer’s or related dementias may be invited to take part in group discussions to explain how you make medication decisions. The team will use those discussions to build choice-based survey questions that ask people to weigh tradeoffs between benefits, side effects, costs, and access. That online survey will be given to a large, nationally representative sample of older English-speaking adults. Researchers will combine the survey results with a risk-adjusted cost-effectiveness model (GRACE) to recommend fair and efficient ways to use new treatments.
Who could benefit from this research
Good fit: Ideal participants are older adults affected by Alzheimer’s disease or related dementias, their caregivers or family members, and other older English-speaking adults comfortable completing web-based surveys.
Not a fit: People who cannot complete online surveys, non-English speakers, or those with severe cognitive impairment who cannot consent are unlikely to participate or directly benefit from joining the project.
Why it matters
Potential benefit: If successful, this work could guide fairer, more personalized decisions about who should receive expensive new Alzheimer’s therapies so choices better match patient values and risks.
How similar studies have performed: Similar patient-preference methods have been used in other diseases to inform policy, but applying discrete choice experiments alongside a GRACE model for Alzheimer’s treatment allocation is relatively new.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Segal, Jodi B. — Johns Hopkins University
- Study coordinator: Segal, Jodi B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.